Download PDF
Thromb Haemost 2020; 120(06): 957-967
DOI: 10.1055/s-0040-1710015
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia

Claudia Djambas Khayat
1   Department of Pediatrics, Hotel-Dieu de France Hospital, Beirut, Lebanon
,
Mohamed El Khorassani
2   Children's Hospital, Mohammed V. University, Rabat, Morocco
,
Selin Aytaç
3   Department of Pediatric Haematology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey
,
Annie Harroche
4   Haemophilia Care Centre, Necker Hospital, Paris, France
,
Amel Dahmane
5   Clinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis, France
,
Sonia Pujol
5   Clinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis, France
,
Céline Henriet 
5   Clinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis, France
,
Philippe de Moerloose
6   Division of Angiology and Hemostasis, Faculty of Medicine, Geneva, Switzerland
,
Françoise Bridey
5   Clinical Development, Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis, France
› Author Affiliations Funding LFB (Les Ulis, France) sponsored the clinical study presented in this paper.
Further Information

Publication History

20 January 2020

23 March 2020

Publication Date:
11 May 2020 (online)

    Permissions and Reprints

Abstract

Objective To date, the use of a fibrinogen concentrate (FC) administered in children with inherited fibrinogen deficiency is poorly documented. Treatment modalities may differ from those of adults. The aim of this study was to investigate the pharmacokinetics (PK), efficacy (bleeding/surgery) and safety of a triple-secured FC (FibCLOT, LFB, France) in young patients aged of 12 years or less.

Methods This was a prospective, non-comparative, multicentre, phase 2–3 study. Estimated PK parameters were based on population PK modelling. Target fibrinogen levels were 1.2 and 1.0 g/L for major and minor events, respectively. In vivo recovery (IVR) was calculated at study entry to tailor the dose.

Results Sixteen afibrinogenaemia patients were treated with FC: 12 included in the PK study (6 aged ≤ 6 years and 6 aged 7–12 years). IVR at 1 hour post-infusion (geometric mean [coefficient of variation]) was 1.91 [20%] mg/dL per mg/kg and results were similar between the two age groups (1.87 [14%]) and (1.96 [27%]) with no statistical differences. Estimated half-life (t 1/2) was 49.0 hours [12%] with no observed differences between groups (46.6 hours [10%] and 51.6 hours [12%]). Overall efficacy was rated as excellent/good in 96.9% of 32 bleeds and in 100% of 11 surgeries. Most of the events (39/43, 90.7%) were managed with one infusion. There was no serious adverse drug reaction.

Conclusion Individually tailored dosing was efficacious in children who exhibited a lower IVR and shorter t 1/2 than those previously reported in adolescent and adult patients emphasising the importance of individualised dose optimisation.

Keywords

afibrinogenaemia - clinical study - fibrinogen - children

Authors' Contributions

C.D.K., M.E.K. and S.A. conducted the study, contributed to patient enrolment and collected the data. A.D. was clinical trial manager, S.P. and C.H. contributed to the analysis of data and edited the manuscript. F.B. conducted the analysis, assessed the literature and wrote the manuscript. P.d.M. supervised the manuscript. All authors reviewed and approved the final manuscript.


 

  • References

  • 1 Mason DY, Ingram GI. Management of the hereditary coagulation disorders. Semin Hematol 1971; 8 (02) 158-188
    PubMedGoogle Scholar
  • 2 Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14 (06) 1151-1158
    CrossrefPubMedGoogle Scholar
  • 3 Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107 (01) 204-206
    CrossrefPubMedGoogle Scholar
  • 4 Yang L, Stanworth S, Baglin T. Cryoprecipitate: an outmoded treatment?. Transfus Med 2012; 22 (05) 315-320
    CrossrefPubMedGoogle Scholar
  • 5 Whincup PH, Gilg JA, Odoki K, Taylor SJC, Cook DG. Age of menarche in contemporary British teenagers: survey of girls born between 1982 and 1986. BMJ 2001; 322 (7294): 1095-1096
    CrossrefPubMedGoogle Scholar
  • 6 Rottenstreich A, Lask A, Schliamser L, Zivelin A, Seligsohn U, Kalish Y. Thromboembolic events in patients with severe inherited fibrinogen deficiency. J Thromb Thrombolysis 2016; 42 (02) 261-266
    CrossrefPubMedGoogle Scholar
  • 7 Sartori MT, Milan M, de Bon E, Fadin M, Pesavento R, Zanon E. Thrombosis of abdominal aorta in congenital afibrinogenemia: case report and review of literature. Haemophilia 2015; 21 (01) 88-94
    CrossrefPubMedGoogle Scholar
  • 8 Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol 2009; 7 (12) 788-790
    PubMedGoogle Scholar
  • 9 Manco-Johnson MJ, Dimichele D, Castaman G. , et al; FIBRINOGEN CONCENTRATE STUDY GROUP. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009; 7 (12) 2064-2069
    CrossrefPubMedGoogle Scholar
  • 10 Ross C, Rangarajan S, Karimi M. , et al. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. J Thromb Haemost 2018; 16 (02) 253-261
    CrossrefPubMedGoogle Scholar
  • 11 Lissitchkov T, Madan B, Djambas Khayat C. , et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost 2020; 18 (04) 815-824
    CrossrefPubMedGoogle Scholar
  • 12 Djambas Khayat C, El Khorassani M, Lambert T. , et al. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency. J Thromb Haemost 2019; 17 (04) 635-644
    CrossrefPubMedGoogle Scholar
  • 13 Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res 2012; 130 (Suppl. 02) S7-S11
    PubMedGoogle Scholar
  • 14 Négrier C, Rothschild C, Goudemand J. , et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost 2008; 6 (09) 1494-1499
    CrossrefPubMedGoogle Scholar
  • 15 Négrier C, Rothschild C, Borg JY. , et al. Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study. Vox Sang 2016; 111 (04) 383-390
    CrossrefPubMedGoogle Scholar
  • 16 Linderkamp O, Versmold HT, Riegel KP, Betke K. Estimation and prediction of blood volume in infants and children. Eur J Pediatr 1977; 125 (04) 227-234
    CrossrefPubMedGoogle Scholar
  • 17 Bellon A, Fuseau E, Roumanie O. , et al. Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: observed age- and body weight-related differences and consequences for dose adjustment in children. Br J Clin Pharmacol 2020; 86 (02) 329-337
    CrossrefPubMedGoogle Scholar
  • 18 WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva: World Health Organization; 2006: 312
    Google Scholar
  • 19 Björkman S. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?. Haemophilia 2013; 19 (06) 882-886
    CrossrefPubMedGoogle Scholar
  • 20 CHMP. 2009 (Committee for Medicinal Products for Human Use). Guideline on Core SmPC for human fibrinogen products. London, United Kingdom: The European Medicines Agency for the Pre-authorisation Evaluation of Medicines for Human Use; ; January 2009. EMEA/CHMP/BPWP/122007/2005
    Google Scholar
  • 21 Casini A, de Moerloose P. Fibrinogen concentrates in hereditary fibrinogen disorders: past, present and future. Haemophilia 2020; 26 (01) 25-32
    CrossrefPubMedGoogle Scholar
  • 22 Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9 (09) 1687-1704
    CrossrefPubMedGoogle Scholar
  • 23 Oruc N, Tokat Y, Killi R, Tombuloglu M, Ilter T. Budd-Chiari syndrome in an afibrinogenemic patient: a paradoxical complication. Dig Dis Sci 2006; 51 (02) 378-380
    CrossrefPubMedGoogle Scholar
  • 24 Khayat CD, Khayat G, Naim B, Tabet G, De Moerloose P, Casini A. Afibrinogenemia: haemorrhagic and/or thrombotic disease?. Haemophilia 2016; 22 (Suppl. 04) 122-123
    PubMedGoogle Scholar
  • 25 Fuchs RJ, Levin J, Tadel M, Merritt W. Perioperative coagulation management in a patient with afibrinogenemia undergoing liver transplantation. Liver Transpl 2007; 13 (05) 752-756
    CrossrefPubMedGoogle Scholar
  • 26 van Meegeren ME, de Rooy JW, Schreuder HW, Brons PP. Bone cysts in patients with afibrinogenaemia: a literature review and two new cases. Haemophilia 2014; 20 (02) 244-248
    CrossrefPubMedGoogle Scholar
  • 27 Aytac S, Kuskonmaz B, Caglar Ö, Gümrük F, Cetin M. Multiple bone cysts in patient with congenital afibrinogenaemia. Haemophilia 2016; 22 (Suppl. 02) 87-88
    CrossrefPubMedGoogle Scholar
  • 28 Ali F, Gökçebay DG, Çulha V, Yarah N, Tunç B, Özbeck N. A rare complication of congenital afibrinogenemia: bone cysts. Turk J Haematol 2017; 34: 183
    PubMedGoogle Scholar